# MAMLD1

## Overview
MAMLD1 (mastermind like domain containing 1) is a gene that encodes a transcriptional co-activator protein involved in the regulation of testosterone production, which is essential for male sex development. The MAMLD1 protein is characterized by its mastermind-like (MAML) motif, which is conserved across various species, and it functions primarily by enhancing the promoter activity of the noncanonical Notch target gene Hes3. This activity is crucial for testosterone biosynthesis, particularly during critical periods of fetal sex development (Fukami2008Mastermindlike). MAMLD1 interacts with several components of the Notch signaling pathway and other transcription factors, forming a complex network that influences gene expression related to sex development (Li2020Disorders; Flück2019Broad). Mutations in the MAMLD1 gene are linked to disorders of sex development (DSD), such as hypospadias and micropenis, highlighting its clinical significance in sexual differentiation (Kalfa2012Screening; Ogata2008<i>MAMLD1).

## Structure
The MAMLD1 protein, encoded by the MAMLD1 gene, features a unique structure with homology to the MAML2 protein, including a conserved mastermind-like (MAML) motif. This motif is present across various species, such as frogs, birds, and mammals, indicating its evolutionary conservation (Fukami2008Mastermindlike). The protein contains several distinct domains, including serine-rich, glutamine-rich, and proline-rich regions, as well as a nuclear localization signal, which are crucial for its function as a transcriptional co-activator (Fukami2008Mastermindlike).

MAMLD1 is involved in transcriptional activation, particularly enhancing the promoter activity of the noncanonical Notch target gene Hes3. This activity occurs independently of the RBP-J binding sites, suggesting a mechanism distinct from canonical Notch signaling (Fukami2008Mastermindlike). The protein does not bind DNA directly but may interact with other transcription factors to exert its effects (Fukami2008Mastermindlike).

The protein's structure and function are affected by mutations, with certain nonsense mutations leading to nonfunctional proteins due to nonsense-mediated decay (Fukami2008Mastermindlike). MAMLD1 also plays a role in testosterone production, as evidenced by reduced testosterone levels following its knockdown in mouse Leydig tumor cells (Fukami2008Mastermindlike).

## Function
MAMLD1 (mastermind like domain containing 1) is a gene that encodes a protein involved in the regulation of testosterone production, which is crucial for male sex development. The MAMLD1 protein functions as a transcriptional co-activator, transactivating the promoter of the noncanonical Notch target gene Hes3, which is involved in testosterone production (Fukami2008Mastermindlike). Although MAMLD1 does not have direct DNA-binding capacity, it can enhance the activity of the Hes3 promoter, suggesting its role in noncanonical Notch signaling pathways (Fukami2008Mastermindlike).

MAMLD1 is expressed in fetal Sertoli and Leydig cells during critical periods of sex development, indicating its importance in normal sexual differentiation and development (Fukami2008Mastermindlike; Nakamura2011Mamld1). The protein contains a target sequence for steroidogenic factor 1 (SF1), which is involved in sex development, further supporting its role in testosterone biosynthesis (Fukami2008Mastermindlike). Knockdown experiments in mouse Leydig tumor cells have shown that reducing Mamld1 expression leads to decreased testosterone production and reduced expression of the Cyp17a1 gene, which is involved in testosterone biosynthesis (Nakamura2011Mamld1). This highlights MAMLD1's specific role in regulating Cyp17a1 expression and testosterone production.

## Clinical Significance
Mutations in the MAMLD1 gene are associated with a range of disorders of sex development (DSD), particularly in individuals with 46,XY karyotype. These mutations can lead to conditions such as hypospadias, micropenis, cryptorchidism, and complete gonadal dysgenesis. Hypospadias, characterized by the abnormal placement of the urethral opening, is one of the most common phenotypes linked to MAMLD1 mutations (Kalfa2012Screening; Ogata2008<i>MAMLD1). 

MAMLD1 mutations can result in compromised testosterone production during critical periods of fetal development, leading to partial hypomasculinization at birth (Fujisawa2016Longterm; Ogata2008<i>MAMLD1). Despite normal testosterone and gonadotropin levels in infancy, some patients with MAMLD1 variants exhibit elevated LH and FSH levels, particularly in cases of precocious puberty (Miyado2021MAMLD1). 

The gene's role in testosterone biosynthesis is supported by evidence of its expression in Leydig and Sertoli cells and its interaction with other genes involved in sex development (Flück2019Broad). MAMLD1 mutations may contribute to DSD through an oligogenic mechanism, where multiple gene defects collectively cause the disorder (Li2020Disorders; Yeste2022A).

## Interactions
MAMLD1 (mastermind like domain containing 1) is involved in several protein interactions, particularly within the Notch signaling pathway. It directly interacts with MAML1, MAML2, and MAML3, which are co-activators in the Notch signaling pathway, and is connected to NOTCH1 and NOTCH2. Through these interactions, MAMLD1 is associated with other genes such as WNT9A, WNT9B, GLI2, GLI3, RET, FLNA, PTPN11, and EYA1, forming a complex network crucial for sex development (Li2020Disorders; Flück2019Broad).

MAMLD1 also plays a role in transcriptional regulation by transactivating the promoter of the noncanonical Notch target gene Hes3. Despite lacking direct DNA-binding capacity, MAMLD1 acts as a transcriptional co-activator, potentially interacting with other transcription factors to exert its effects (Fukami2008Mastermindlike). The protein's interaction with MAML2 in nuclear bodies suggests a role in transcriptional complexes, although certain mutations can disrupt this localization (Fukami2008Mastermindlike).

These interactions highlight MAMLD1's involvement in the regulation of gene expression and its potential impact on disorders of sex development through complex genetic networks (Li2020Disorders).


## References


[1. (Yeste2022A) Diego Yeste, Cristina Aguilar-Riera, Gennaro Canestrino, Paula Fernández-Alvarez, María Clemente, and Núria Camats-Tarruella. A new mamld1 variant in an infant with microphallus and hypospadias with hormonal pattern suggesting partial hypogonadotropic hypogonadism—case report. Frontiers in Endocrinology, June 2022. URL: http://dx.doi.org/10.3389/fendo.2022.884107, doi:10.3389/fendo.2022.884107. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2022.884107)

[2. (Flück2019Broad) Christa E. Flück, Laura Audí, Mónica Fernández-Cancio, Kay-Sara Sauter, Idoia Martinez de LaPiscina, Luis Castaño, Isabel Esteva, and Núria Camats. Broad phenotypes of disorders/differences of sex development in mamld1 patients through oligogenic disease. Frontiers in Genetics, August 2019. URL: http://dx.doi.org/10.3389/fgene.2019.00746, doi:10.3389/fgene.2019.00746. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2019.00746)

[3. (Li2020Disorders) Lele Li, Fenqi Gao, Lijun Fan, Chang Su, Xuejun Liang, and ChunXiu Gong. Disorders of sex development in individuals harbouring mamld1 variants: wes and interactome evidence of oligogenic inheritance. Frontiers in Endocrinology, December 2020. URL: http://dx.doi.org/10.3389/fendo.2020.582516, doi:10.3389/fendo.2020.582516. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2020.582516)

[4. (Fukami2008Mastermindlike) Maki Fukami, Yuka Wada, Michiyo Okada, Fumiko Kato, Noriyuki Katsumata, Takashi Baba, Ken-ichirou Morohashi, Jocelyn Laporte, Motoo Kitagawa, and Tsutomu Ogata. Mastermind-like domain-containing 1 (mamld1 or cxorf6) transactivates the hes3 promoter, augments testosterone production, and contains the sf1 target sequence. Journal of Biological Chemistry, 283(9):5525–5532, February 2008. URL: http://dx.doi.org/10.1074/jbc.M703289200, doi:10.1074/jbc.m703289200. This article has 91 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M703289200)

[5. (Fujisawa2016Longterm) Yasuko Fujisawa, Maki Fukami, Tomonobu Hasegawa, Ayumi Uematsu, Koji Muroya, and Tsutomu Ogata. Long-term clinical course in three patients with &lt;i&gt;mamld1&lt;/i&gt; mutations. Endocrine Journal, 63(9):835–839, 2016. URL: http://dx.doi.org/10.1507/endocrj.ej16-0143, doi:10.1507/endocrj.ej16-0143. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1507/endocrj.ej16-0143)

[6. (Miyado2021MAMLD1) Mami Miyado, Maki Fukami, and Tsutomu Ogata. Mamld1 and differences/disorders of sex development: an update. Sexual Development, 16(2–3):126–137, October 2021. URL: http://dx.doi.org/10.1159/000519298, doi:10.1159/000519298. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000519298)

[7. (Nakamura2011Mamld1) Michiko Nakamura, Maki Fukami, Fumihiro Sugawa, Mami Miyado, Katsuya Nonomura, and Tsutomu Ogata. Mamld1 knockdown reduces testosterone production and cyp17a1 expression in mouse leydig tumor cells. PLoS ONE, 6(4):e19123, April 2011. URL: http://dx.doi.org/10.1371/journal.pone.0019123, doi:10.1371/journal.pone.0019123. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0019123)

[8. (Kalfa2012Screening) Nicolas Kalfa, Maki Fukami, Pascal Philibert, Francoise Audran, Catherine Pienkowski, Jacques Weill, Graziella Pinto, Sylvie Manouvrier, Michel Polak, Totsumo Ogata, and Charles Sultan. Screening of mamld1 mutations in 70 children with 46,xy dsd: identification and functional analysis of two new mutations. PLoS ONE, 7(3):e32505, March 2012. URL: http://dx.doi.org/10.1371/journal.pone.0032505, doi:10.1371/journal.pone.0032505. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0032505)